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ABSTRACT
Platelet-rich plasma (PRP) has emerged as a new treatment modality in regenerative plastic surgery,
and preliminary evidence suggests that it might have a beneficial role in hair regrowth. Here, we re-
port the results of a randomized, evaluator-blinded, placebo-controlled, half-head group study to
compare, with the aid of computerized trichograms, hair regrowth with PRP versus placebo. The
safety and clinical efficacy of autologous PRP injections for pattern hair loss were investigated.
PRP, prepared from a small volume of blood, was injected on half of the selected patients’ scalpswith
pattern hair loss. The other half was treated with placebo. Three treatments were administered to
each patient at 30-day intervals. The endpoints were hair regrowth, hair dystrophy as measured
by dermoscopy, burning or itching sensation, and cell proliferation as measured by Ki67 evaluation.
Patients were followed for 2 years. Of the 23 patients enrolled, 3 were excluded. At the end of the 3
treatment cycles, the patients presented clinical improvement in the mean number of hairs, with
amean increase of 33.6 hairs in the target area, and amean increase in total hair density of 45.9 hairs
per cm2 compared with baseline values. No side effects were noted during treatment. Microscopic
evaluation showed the increase of epidermis thickness and of the number of hair follicles 2 weeks
after the last PRP treatment compared with baseline value (p < .05). We also observed an increase
of Ki67+ keratinocytes in the epidermis and of hair follicular bulge cells, and a slight increase of small
blood vessels around hair follicles in the treated skin compared with baseline (p < .05). Relapse of
androgenic alopecia was not evaluated in all patients until 12 months after the last treatment. After
12 months, 4 patients reported progressive hair loss; this was more evident 16 months after the last
treatment. Those four patients were re-treated. Our data clearly highlight the positive effects of PRP
injections on male pattern hair loss and absence of major side effects. PRP may serve as a safe and
effective treatment option against hair loss; more extensive controlled studies are needed. STEM
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SIGNIFICANCE
Platelet-rich plasma (PRP) has emerged as a new treatment modality in regenerative plastic surgery,
andpreliminary evidence suggests that itmight have abeneficial role in hair regrowth. Here, the results
of a randomized, placebo-controlled, half-head group study to compare the hair regrowth with PRP
versus placebo are reported. Hair regrowth was quantified by a blinded evaluator using computerized
trichograms. The safety and clinical efficacy of autologous PRP injections for pattern hair loss were in-
vestigated. Of the 23 patients enrolled, 3 were excluded. At the end of the 3 treatment cycles, the
patients presented clinical improvement in the mean number of hairs, with a mean increase of 33.6
hairs in the target area and a mean increase in total hair density of 45.9 hairs per cm2 compared with
baseline values. No side effects were noted during treatment. The data clearly highlight the positive
effects of PRP injections on male pattern hair loss and absence of major side effects.
INTRODUCTION
Androgenic alopecia is a common, chronic hair loss
disorder. It is characterized by progressive hair loss,
affecting both sexes. It affects up to 80% of white
men and 40% of women. A number of products
have been proposed as hair-loss therapies. Drug
therapies specifically approved by the U.S. Food and
Drug Administration (FDA) for treating androgenic
alopecia are limited to minoxidil and finasteride.
Both can be used alone or combined [1].
Proponents of platelet-rich plasma (PRP)
technology suggest that its benefits include an in-
crease in hard- and soft-tissue wound healing. In
addition, the role of PRP for the treatment of al-
opecia (areata and androgenic) has been demon-
strated in recent reports [2–4]. The activation of
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factors, including transforming growth factor (TGF), platelet-
derived growth factor (PDGF),vascular endothelial growth fac-
tor (VEGF), epidermal growth factor (EGF), insulin-like growth
factor, and interleukin-1 [3]. It is proposed that growth factors
released from platelets may act on stem cells in the bulge area
of the follicles, stimulating the development of new follicles and
promoting neovascularization [3]. In fact, in the bulge area, prim-
itive stem cells of ectodermal origin are found, giving origin to epi-
dermal cells and sebaceous glands. In matrix, germinative cells of
mesenchymal origin are found at the dermal papilla. Interactions
between these two kinds of cells aswell as with binding growth fac-
tors (PDGF, TGF-b, and VEGF) activate the proliferative phase of the
hair, giving rise to the future follicular unit [1]. For these reasons,
Gkini et al. [1], and Khatu et al. [3] have reported in two different
works that PRP could serve as a potential treatment for androgenic
alopecia.
Rinaldi et al. [4] described the use of PRP in alopecia areata
(AA). The results of this pilot study suggest that PRP may serve
as a safe and effective treatment option in AA, and the authors call
for more extensive, controlled studies with this method. Uebel
et al. [5] showed that pretreatment of follicular units with PRP be-
fore transplantation resulted in improved hair growth and density.
PRPhasbeen reported to induce theproliferationofdermal papilla
cellsbyupregulating fibroblastgrowthfactor7(FGF-7)andb-catenin,
as well as extracellular signal-related kinase (ERK) and Akt sig-
naling [2]. Anagen-associated angiogenesis has been suggested as
one of the important factors in active hair growth, because of the
secretion of VEGF by the keratinocytes of the outer root sheath and
fibroblasts of the dermal papilla [6, 7]. Increased secretion of VEGF
influences growth of normal and pathological dermal structures
[8]. Tobin et al. [9] reported the hair folliclemesenchyme exhibits
significant hair cycle-associated plasticity.Modulation of these cell
interchanges is likely to be important during clinically important
hair follicle transformations (e.g., vellus to terminal and terminal
to vellus during androgenetic alopecia [9]). Injection of PRP has
been demonstrated to improve cutaneous ischemic conditions
and to increase vascular structures around hair follicles [10].Many
of the current treatmentmodalities for pattern hair loss have been
shown tomodulate angiogenesis and enhance blood flow [11].We
aimed to clarify the effects of PRP scalp injection in humans af-
fected by androgenic alopecia. It could improve hair regrowth,
thereby making the PRP procedure an alternative to finasteride
or minoxidil. The data we report demonstrate the clinical efficacy
and histological safety of PRP treatment. Moreover, patients’ sat-
isfaction and computerized trichogram analysis have confirmed
the quality of the results.
MATERIALS AND METHODS
Study Overview
This was a randomized, placebo-controlled, half-head group study
conducted by plastic surgeons, biologists, pathologists of the Uni-
versity of Rome “Tor Vergata,” and a dermatologist of the Catholic
Universityof theSacredHeartofRome.Evaluatorsofcomputerized
trichograms were blinded to treatment. A follow-up period of
2 years was chosen because a reduction in the effect of PRP by
14 months after the last treatment has been observed.
The diagnosis of male pattern hair loss (MPHL) was estab-
lishedon thebasis of a detailedmedical history (anydrugs causing
hair loss), clinical examination, trichoscopic features (more than
20% variability in hair diameter between affected and unin-
volved areas) and laboratory tests. Laboratory tests to exclude
other hair loss causes, such as anemia, poor nutrition, thyroid
dysfunction, and syphilis, included the following: complete
blood cell count; measurement of serum levels of iron, serum
ferritin, total iron-binding capacity, folic acid, T3, T4, thyroid-
stimulating hormone, fT3, fT4, antithyroid peroxidase, and
testosterone; and a Venereal Disease Research Laboratory blood
test for syphilis.
The stage of alopecia was evaluated according to the
Hamilton-Norwood scale. The study protocol complied with the
Declaration of Helsinki. All patients provided written informed
consent before participating in the study.
Patient Population and Randomization
The study enrolled 23 male patients. Inclusion criteria were
age 19–63 years; MPHL from stage IIa to stage IV according to
the Norwood-Hamilton classification (Table 1); and the partici-
pant was considered suitable for PRP injection from a surgical
point of view as assessed by the expected cosmetic results
and the transfusional service.
Exclusion criteria were divided into two types: local and sys-
temic. The systemic criteria included platelets disorders, thrombo-
cytopenia, antiaggregating therapy, systemic treatments for
MPHL (such as finasteride, dutasteride, and antiandrogens) in
the previous 12 months, bone marrow aplasia, uncompensated
diabetes, sepsis, and cancer. The local criteria included MPHL
stages V–VII, topical treatments forMHPL (e.g., minoxidil, prosta-
glandin, analogs, retinoids, and corticosteroids) in the previous
12 months, and withdrawal of informed consent. Three patients
with a propensity for keloids and patients whowere immunosup-
pressed were excluded. In addition, the numbers of platelets in
PRP obtained from all participants weremicroscopically counted.
All participants included were assessed by two experts in plastic
surgery.
The allocation sequencewas generated using an online ran-
domization generator andwas concealed by a person unrelated
to the trial management group. The participants, study person-
nel, and outcome assessors were all blinded to treatment allo-
cation, and blinding was maintained until all data had been
analyzed.
The primary outcomewas residual hair count and hair density
based on computerized trichogram (Fig. 1). The secondary out-
comesweremicroscopic evaluation (Fig. 2) of theepidermis thick-
ness in PRP-treated hair skin and increase in the number of
follicles compared with baseline value and evaluation of safety
and feasibility (Fig. 3).
Procedures
PRP was prepared from a small volume of blood (18 ml) according
to the method of the Cascade-Selphyl-Esforax system (Aesthetic
Factors, LLC, Wayne, NJ, http://www.selphyl.com), with modifica-
tions [12–14], and from 60 ml of blood according to the P.R.L.
Platelet Rich Lipotransfert system (CORIOS Soc. Coop, San Giuliano
Milanese, Italy, http://www.corios.it), with modifications, using PRP
alone (C-punt; Biomed Device, Modena, Itlay, http://www.
biomeddevice.it) without the combined use of stromal vascular
fraction cells. Briefly, blood was taken from a peripheral vein
using sodium citrate as an anticoagulant. The current systems
for preparing platelet concentrations use various centrifuges
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(in the Cascade-Selphyl-Esforax procedure, we used 1,100g for
10minutes; in the P.R.L. Platelet Rich Lipotransfert system,we
used 1,200 rpm for 10minutes). PRP was prepared in all cases
with approval of the transfusional service. Although the method
of preparation is not selective and may include leukocytes, the
final aim is to obtain a platelet pellet. Growth factors are
secreted only once platelet activation begins, which, in turn,
is stimulated by calcium (Ca2+). To optimize the secretion process,
the optimum concentration of Ca2+ was previously determined
[12, 13]. Then, autologous PRP, not activated obtained after cen-
trifugation (9ml), was switched with 10-ml tubes containing Ca2+.
Autologous PRP, not activated, obtained by the P.R.L. Platelet Rich
Lipotransfert procedure after centrifugation (20 ml), was inserted
in a light selector device. At the end of the procedure, 9 ml of PRP
was harvested.
Foreachpatient, thescalpaffectedbyhair losswasdivided into
fourareas (frontal, parietal, vertex, andoccipital)andcleansedwith
70%alcohol; local anesthesiawas not injected in the treated areas.
PRP (0.1 ml/cm2) was injected in selected areas of the scalp. PRP
injections were performedwith a 30-gauge, 1-ml Luer-lock syringe
(Fig. 4). Interfollicular injection of PRP was performed 3 times in
eachpatient at intervals of 30days. Patientswith hair loss localized
to the frontal andparietal areaswere injectedwith the PRPonly on
the frontal areas; the parietal areawas treatedwith placebo (injec-
tion of physiological solution). Patientswith hair loss in the parietal
andvertexpartswere injectedwith thePRPonly in theparietal part
of the scalp; the vertex area was treated with placebo (injection of
physiological solution). The same number of injections was re-
peated in the scalp half treated with PRP and in the half treated
with placebo. Photographs of the areas of a sample scalp treated
with PRP are shown in Figure 1.
All patientswereevaluated in6 stages: T0, beginningof study;
T1, 2months; T2, 6months; T3, 12months, T4, 16months; andT5,
24 months. The effects of the treatment on hair growth were
assessed in all patientswith thehelpof global photography, physi-
cian’s and patient’s global assessment scale, and standardized
phototrichograms.
Phototrichogramswere taken of all scalps by a trained evaluator
using Fotofinder video-epiluminescence microscopy (FotoFinder
Systems; http://www.fotofinder.de) in combination with the
Trichoscan digital image analysis (Tricholog GmbH and Datinf
GmbH; http://trichoscan.com). TrichoScan is a digital software-
supported epiluminescence technique for measuring hair count
(number of hairs per 0.65 cm2), hair density (number of hairs per
cm2), hair diameter, anagen-to-telogen ratio, and vellus hair-to-
terminal hair ratio. To determine the quality of hair leading to an
increased hair density, it is important to differentiate the number
of terminal and vellus hairs. In TrichoScan analysis, all hairs with a
diameter.40mmare categorized as terminal hairs; thosewith lesser
diameter are categorized as vellus hairs. In all patients, in both the
treatmentandcontrolhalf-heads, twotransitional areasofhair loss
were defined and marked with a semipermanent tattoo for the sub-
sequent trichogram. In the target area, hairs were clipped and dyed
brown for 10 minutes to improve the hair contrast for the analytic
software. The evaluator of the computerized trichogram analysis
wasblinded regarding the treatmentandcontrol areasof the scalp,
and was not involved in administration of treatment.
Histopathological Evaluation
Incisional punch biopsies (diameter: 3 mm) of the hair skin were
obtained at baseline and after 2 months from the last PRP treat-
ment, and fixed in buffered formalin. Morphometric analysis [15]
was performed on hematoxylin-and eosin-stained paraffin serial
sections by evaluating the thickness of epidermis and the number
of follicles per mm2, according to the method [16]. All samples
Figure 1. Trichoscan digital image analysis. (A, B): In these images,
preoperative hair count was 67.5 hairs per cm2; density was 120.1
hairs per cm2; and proportions of anagen and telogen hairs were
52.2% and 47.8%, respectively. (C, D): In these images, postoperative
hair count was 128.5 hairs per cm2; density was 228.6 hairs per cm2;
and proportions of anagen and telogen hairs were 37.6% and 62.4%,
respectively.
Table 1. Summary of patients’ characteristics
Case no. Age, years
Hamilton-Norwood
classification stage Injection site
1 20 IIa Frontal
2 32 IIa Frontal
3 42 III Parietal
4 40 III vertex Parietal
5 41 IIa Frontal
6 52 IV Parietal and vertex
7 25 III vertex Parietal
8 26 III Parietal
9 28 III Frontal
10 21 IIa Frontal
11 28 III Parietal
12 35 IIa Frontal
13 46 III Parietal
14 57 III vertex Parietal
15 40 IIa Frontal
16 63 IV Parietal and vertex
17 27 III vertex Parietal
18 26 III Parietal
19 28 III Frontal
20 38 IIa Frontal
21 31 IIa Frontal
22 34 IIa Frontal
23 19 IIa Frontal
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were cut perpendicularly at the skin surface and embedded, pay-
ing attention to the correct orientation.
Immunohistochemistry
Immunohistochemistry was performed using mouse monoclonal
anti-Ki67 (DakoCytomation;Dako;http://www.dako.com) [17–19].
The percentage of Ki67+ cells in the basal layer of the epidermis and
in the outer root sheath of hair follicles, and the number of vessels
per mm2 were calculated according to morphometric criteria [18].
Statistical Analysis
Statistical analyses of the data were performed using the Statis-
tical Package for the Social Sciences (SPSS), version 19.0 (IBM;
http://www-01.ibm.com). The normality of quantitative varia-
bles was tested by the Kolmogorov-Smirnov test. Hair density
was expressed as mean plus or minus the SD. Hair density differ-
ences between the different time points were assessed by one-
way repeated measures analysis of variance; post hoc analysis
wasperformedusing theSidak test.All testswere2-tailedandsta-
tistical significance was considered for p , .05.
Figure 2. Epidermis thickness and the number of follicles of hair skin are increased after PRP treatment. (A, B): Representative photomicro-
graphsofhair skin epidermis atbaseline (A)and2weeksafter PRP treatment (B) (hematoxylin andeosin stain; originalmagnification:3200). (C):
Bar graph of epidermis thickness. (D, E): Representative photomicrographs of dermal hair follicles at baseline (D) and after PRP treatment (E)
(hematoxylin and eosin stain; original magnification: 3100). (F): Bar graph of the number of hair follicles per mm2 at baseline and after PRP
treatment. p, p, .05. Abbreviation: PRP, platelet-rich plasma.
Figure 3. Proliferation of epidermis basal cells and hair follicular bulge cells is increased after PRP treatment. (A, B): Representative photo-
micrographs of Ki67+ proliferating cells by immunohistochemistry of hair skin epidermis at baseline (A)andafter PRP treatment (B) (hematoxylin
and eosin stain; original magnification:3200). (C):Morphometric analysis of Ki67+ cells of hair skin epidermis at baseline and after PRP treat-
ment. (D, E):Representative photomicrographs of Ki67+proliferating cells by immunohistochemistry of hair follicles at baseline (D)andafterPRP
treatment (E) (hematoxylin and eosin stain; original magnification:3100). (F):Morphometric analysis of the percentage of Ki67+ nuclei in hair
follicles at baseline and after PRP treatment. p, p, .05. Abbreviation: PRP, platelet-rich plasma.
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RESULTS
The various hair-growth parameters measured after 3 months of
the first treatmentwere comparedwith thebaseline studybefore
treatment and between both treatment and control areas. Mean
total hair counts, hair density, and terminal and vellus hair den-
sities for the treatment and control areas are listed in Table 2.
Atbaseline, therewereno statistical differences inhair count, hair
density, and terminal and anagen hair densities between the
treatment and control area of the scalp.
The results of this study showed a significant increase in the
mean hair count for the treatment area after 3months (3months
vs. 0month), with amean increase of 33.6 hairs in the target area
compared with baseline, while the control area showed a mean
decrease of 3.2 hairs (control vs. treatment: p, .0001). Accord-
ingly, in the treatment area, a mean increase in total hair density
of 45.9 hairs per cm2 compared with baseline was observed after
3 months, and the control area displayed a mean decrease of
3.8 hairs per cm2) in hair density at the same time (control vs.
treatment: p, .0001). In addition, terminal hair density improved
significantly by 40.1 hairs per cm2 in the treatment area compared
with baseline, while it decreased by 5.6 hairs per cm2 in the control
area of the scalp (control vs. treatment: p = .0003). There were no
statistically significant differences in vellus hair density between
the study and the control area after 3 months.
Microscopic evaluation showed the increase of epidermis
thickness in PRP-treated hair skin after 2 weeks from the last
PRP treatment compared with baseline value (p , .05). Two-
week PRP treatment was also accompanied by an increase in the
number of follicles comparedwith baseline value (p, .05) (Fig. 2).
To better report the effects of PRP, we investigated the prolifer-
ation of epidermal and hair follicular bulge cells. After 2 weeks from
the last treatment, we observed an increase of Ki67+ basal keratino-
cytes of epidermis and of hair follicular bulge cells compared with
baseline (p, .05) (Fig. 3). PRP treatment also was associated with
an increase in small blood vessels around hair follicles in the treated
skin treated compared with baseline (p, .05). The clinical result of
the areas of onepatient’s scalp treatedwith PRP is shown in Figure 5.
The relapse of androgenic alopecia in all patients was not
evaluated until 12 months after the last treatment. Four patients
reported progressive hair loss that was more evident 16 months
after the last treatment. Those four patients were treated again
with three PRP injections.
DISCUSSION
Androgenic alopecia remains the most common hair disorder
without satisfactory treatment. Since androgenetic alopecia
is characterized by a shortened anagen phase and miniaturiza-
tion of terminal to vellus hair, current therapeutic strategies
target cellular proliferation and differentiation during the hair
cycle [1].
Hair transplant and a number of products have been pro-
posed as hair-loss therapies. Drug therapies approved by the
FDAwere limited to minoxidil and finasteride used alone or com-
bined [1]. Minoxidil prolongs anagen and increases hair follicle
size through stimulationofpotassiumchannels andprostaglandin
endoperoxide synthase-1, which increases the level of prosta-
glandin E2 [11].Minoxidil promotes the survival of dermal papilla
cells by increasing Bcl-2/Bax ratio and by activating ERK and Akt
[20]. Oral finasteride also induces the prolongation of anagen
hairs, which results in gradual thickening and elongation of the
hairs [21]. In addition, finasteride has been shown to reduce
the pattern hair loss associated with increased expression of
caspases and apoptosis inhibitors; therefore, it is ultimately sug-
gested to activate anagen hair growth [22, 23].
There are new data regarding PRP’s potential effect on hair.
Antiapoptotic effects of activated PRP have been suggested as
one of the major contributing factors stimulating hair growth
[2, 24]. PRP-induced activation of antiapoptotic regulators, such
as theBcl-2 protein andAkt signaling, prolongs the survival of der-
mal papilla cells during the hair cycle [2, 25]. In addition, the upre-
gulation of FGF-7/b-catenin signaling pathways with PRP treatment
is suggested to stimulate hair growth by inducing follicular stem
cell differentiation as well as prolonging the anagen phase of the
hair growth cycle [2, 26]. It also appears to increase the perifollicular
vascular plexus through the increase of VEGF and PDGF levels,
which have angiogenic potential [1].
Gkini et al. [1] reported in a nonrandomized trial the efficacy of
PRP injection in 22 patients affected by androgenic alopecia. This
prospective cohort study was based on 3 treatment sessions with
an interval of 3 weeks. At 6months from the beginning of the treat-
ment, a booster sessionwas alsoperformed. Thepatients presented
hair density significantly increased at 6weeks (154.806 34.39 hairs
per cm2), at 3 months (170.706 37.81 hairs per cm2), at 6 months
(156.236 37.75 hairs per cm2), and at 1 year (153.706 39.92 hairs
per cm2) compared with the onset of therapy (p, .001).
Kang et al. [27] reported the clinical efficacy of injection of CD34+
cell-containing PRPpreparations formale and female pattern hair
loss. In this study, 3months after the first treatment, the 13 patients
Table 2. Relevant hair-growth parameters assessed by Trichoscan
analysis for the treatment and control half-head areas at baseline and
after 14 weeks
Hair-growth parameter Time Treatment area Control area
Hair count, mean 6 SD Baseline 89.66 20.9 91.16 22.4
T1 123.26 33.7 87.96 20.5
Hair density, mean 6 SD,
no. per cm2
Baseline 161.26 41.9 166.56 45.6
T1 207.16 56.3 170.36 42.1
Terminal hair density,
mean6 SD, no. per cm2
Baseline 149.16 43.1 154.56 40.4
T1 189.26 46.6 148.96 41.1
Vellus hair density,
mean6 SD, no. per cm2
Baseline 16.66 8.9 16.96 11.6
T1 18.56 8.7 17.96 13.8
Abbreviations: T1, time 1 (14 weeks after treatment).
Figure 4. Intraoperative injection with the platelet-rich plasma (PRP)
at0.1ml/cm2. (A): Intraoperative injectionwithPRPat0.1ml/cm2 in the
frontal line. (B): At the end of injection with PRP (0.1 ml/cm2).
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presented clinical improvement in themean number of hairs (20.5%
6 17.0%), mean hair thickness (31.3%6 30.1%, and mean 2-point
score (84.4%6 51.7%) comparedwith baseline values. At 6months,
the patients presented clinical improvement in mean hair count
(29.2%6 17.8%), mean hair thickness (46.4%6 37.5%), and mean
2-point score (121.3%6 66.8%) compared with baseline.
Khatu et al. [3] reported a significant reduction in hair loss be-
tween first and fourth PRP injection in a group of 11male patients
affected by androgenic alopecia. In this study, hair count in-
creased from average number of 71 hair follicular units to 93
hair follicular units. Therefore, the average mean gain was 22.09
follicular units per cm2.
In a study conducted with 64 patients affected by androgenic
alopecia, Schiavone et al. [28] reported the results obtained after
two injections of leukocyte platelet-rich plasma (L-PRP) with the
addition of concentrated plasmatic proteins, at baseline and after
3 months (single spin at baseline and double-spin centrifugation
at 3months).Macrophotographswere taken at baseline andafter
6 months, and 2 independent evaluators rated them using the
Jaeschke rating of clinical change. Themean change in clinical rat-
ingwas3.2 (95%confidence interval [CI]: 2.9–3.5) and3.9 (95%CI:
3.5–4.3), respectively, and the proportion of patients reaching
a clinically important difference was 40.6% and 54.7%, respec-
tively, according to the 2 evaluators.
Rinaldi et al. [4] described the efficacy and safety of PRP in the
first report on alopecia areata in a randomized, double-blind,
placebo- and active-controlled, half-head, parallel-group study. A
total of 45 patients with alopecia areatawere randomized to receive
intralesional injections of PRP, triamcinolone acetonide (TrA), or
placebo on half of their scalp. The other half was not treated.
Three treatments were administered to each patient at intervals
of 1 month. Patients treated with PRP had significantly increased
hair regrowthcomparedwith those treatedwithTrA; 27%ofpatients
treated with TrA achieved complete remission at 12 months, com-
pared with 60% of patients treated with PRP, which is significantly
higher than that seen in TrA- and placebo-treated patients. At
6 months, 38% of the patients in the TrA group had relapse of dis-
ease, while no patients from the PRP grouphad relapse at this time
point. At 12 months, 71% of the patients in the TrA group experi-
enced relapse of disease, while only 31% of the patients in the PRP
grouphad a relapse.Whereas 96%of the patients in the PRP group
had regrowth of fully pigmented hair from the beginning of hair
growth, only 25% in the TrA group had pigmented hair at the be-
ginning of hair regrowth.
In accordance with these results, Rinaldi et al. [4] reported
that both PRP and TrA decreased the number of dystrophic hairs
as assessed by dermoscopic photomicrographs, and also de-
creased the itching or burning sensation of the patients. Both
PRP and TrA significantly increased the levels of Ki67 in alopecia
areata patches compared with placebo, and levels were signifi-
cantly higher after PRP treatment compared with TrA. The effect
of PRP on Ki67 levels was evident already after 2months, andwas
sustained throughout the study period (1 year) [4].
Now the questions are as follows:What is the quantity of PRP
to inject in the selected areas? What is the diameter of selected
areas in which to inject PRP? What is the better method to pre-
pare PRP? What is the better method to inject PRP? What is
the best concentration of platelets?
Gkini et al. [1] injected PRP at a dose of 0.05–0.1ml/cm2, with
a 27-gauge needle using BD-Luer Lok 1-ml syringes (Becton,
Dickinson, and Company; https://www.bd.com). Nappage tech-
nique was performed at a depth of 1.5–2.5mm. The blood harvested
(16 ml) was introduced into two tubes (Regen-BCT; Regen Lab;
http://www.regenlab.com) and centrifuged for 5 minutes at
1,500g. Then, 2 ml of upper supernatant plasma (platelet-poor
plasma [PPP])was removed fromeach tube; 3ml of PRPwas yielded,
which was resuspended by gentle inversions of the tube. Total
amount of yielded PRP was approximately 6 ml. The activation
process included the addition of calcium gluconate in a 1:9 ratio
(0.1 ml calcium gluconate per 0.9 ml of PRP). The platelets in
whole blood and PRP were microscopically counted and mean
platelet counts were 1.93 105 and 1.1023 106 platelets/ml, re-
spectively. The concentration of platelets in PRP was approxi-
mately 5.8 times as great as that in whole blood.
Khatu et al. [3] prepared PRP by collecting 20 ml of fresh
blood. The tubes were subjected at first centrifugation to 1,500
revolutions per minute for 6minutes. This tube underwent a sec-
ond centrifugation, which was longer and faster than the first,
called a “hard spin”, at 2,500 revolutions per minute for 15
minutes. The upper layer containing PPP was discarded and the
lower layer of PRPwas loaded in an insulin syringe containing cal-
cium chloride (one part calcium chloride and nine parts PRP) as an
activator. Nappage techniquewas performed at a depth of a 1 cm3
1 cm over the right parietal area in the midpupillary line, 10 cm
proximal to the right eyebrow in each patient. A total volume of
2–3 ml was injected.
Rinaldi et al. [4] preparedPRPby collecting36ml of peripheral
blood. The tubes were centrifuged for 8 minutes at 70g. The PRP
fraction was separated and suspended with calcium gluconate.
In our study, PRP was prepared from a small volume of blood
(18 ml) according to the method of the Cascade-Selphyl-Esforax
system [12, 13].We centrifuged the blood harvested in two tubes
at 1,100g for 10 minutes. PRP was prepared in all cases with ap-
proval of the transfusional service. Then, autologous PRP thatwas
not activated after centrifugation (9ml) was switched with 10-ml
tubes containing Ca2+ extracted by the Cascade-Selphyl-Esforax
Kit. The PRP (0.1 ml/cm2) was injected in selected areas of the
scalp in the amount. It is suggested that a sufficient number of
platelets could be obtained in all patients by using an automated
PRP preparation system.
CONCLUSION
Giusti et al. [29] demonstrated that theoptimalplatelet concentra-
tion for the induction of angiogenesis in human endothelial cells
Figure 5. A 29-year-old male patient affected by hair loss. (A): Pre-
operative situation of the frontal line and parietal area. (B): Postop-
erative situation of the frontal line and parietal area 2weeks after the
last treatment with increase in the hair count and hair density.
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was 1.5 million platelets per microliter, whereas excessively high
concentrations of platelets were suggested to decrease the angio-
genic potential [29]. In this study, a mean of 1,484,555.6 platelets
per microliter in the PRP preparation could effectively stimulate
follicular and perifollicular angiogenesis, which is suggested to be
one of the major factors in active hair growth [5, 11]. Our data and
data published by us [19] and other authors since 2011 suggest that
the injection of PRP preparations has a positive therapeutic effect
on male androgenic alopecia without major side effects.
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